STOCK TITAN

Gilead (GILD) Rule 144 Notice: Recent Insider Sales Disclosed

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Gilead Sciences (GILD) Form 144 notice for proposed and recent insider sales. The filing shows a proposed sale of 2,500 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $283,925 and lists 1,240,806,916 shares outstanding. The filer, identified in the sales history as Andrew Dickinson, sold 2,500 shares on 06/16/2025 for $275,425, 2,500 shares on 07/15/2025 for $277,575, and 2,500 shares on 08/15/2025 for $296,325, totaling 7,500 shares sold in the past three months. Acquisition records show the securities were restricted stock acquired on 03/10/2022 (1,981 shares) and 03/10/2024 (519 shares). The filer certifies no undisclosed material adverse information and references Rule 10b5-1 language.

Positive

  • None.

Negative

  • Insider dispositions: The filer sold a total of 7,500 shares across June–August 2025, which may be viewed negatively by some investors monitoring insider sales patterns.
  • Ongoing selling: There is a proposed additional sale of 2,500 shares on 09/15/2025, indicating continued insider liquidity events.

Insights

TL;DR: Insider has sold 7,500 GILD shares recently; proposed 2,500-share sale is routine disclosure under Rule 144.

The sales by Andrew Dickinson are disclosed across June, July and August 2025 totaling 7,500 common shares, with a proposed additional sale of 2,500 shares on 09/15/2025. The transactions were routed through Morgan Stanley Smith Barney LLC. The filing documents that the shares originated as restricted stock grants in 2022 and 2024, which explains eligibility for Rule 144 sales once conditions are met. Given the relatively small size versus the 1.24 billion shares outstanding, these sales are unlikely to be materially dilutive or immediately valuation-changing, but they are relevant for monitoring insider disposition patterns.

TL;DR: Routine insider dispositions are disclosed properly; monitor for pattern but filing itself shows standard compliance.

The Form 144 provides required disclosure: seller identity, broker, amounts, dates, and acquisition provenance (restricted stock). The signer affirms absence of undisclosed material information and references Rule 10b5-1 procedural language. From a governance perspective, the document indicates compliance with Section 144 reporting obligations. The magnitude (2,500-share proposed sale; 7,500 shares sold in three months) is small relative to total outstanding shares, reducing immediate governance concern, though repeated insider sales could be of interest to investors assessing insider confidence.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the GILD Form 144 disclose about recent insider sales?

The filing shows Andrew Dickinson sold 2,500 shares on 06/16/2025 for $275,425, 2,500 on 07/15/2025 for $277,575, and 2,500 on 08/15/2025 for $296,325.

How many shares is the proposed sale and what is its market value?

The proposed sale is 2,500 common shares with an aggregate market value of $283,925, to be executed via Morgan Stanley Smith Barney LLC.

What is the source of the shares being sold under Rule 144?

The securities were acquired as restricted stock: 1,981 shares on 03/10/2022 and 519 shares on 03/10/2024 from the issuer.

How large are these sales relative to Gilead's outstanding shares?

The filing reports 1,240,806,916 shares outstanding; the recent 7,500-share sales and proposed 2,500-share sale are immaterial relative to that total.

Who is the broker handling the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

155.92B
1.24B
0.1%
90.75%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY